Lisa Kamen

1.1k total citations · 1 hit paper
12 papers, 732 citations indexed

About

Lisa Kamen is a scholar working on Psychiatry and Mental health, Cognitive Neuroscience and Pathology and Forensic Medicine. According to data from OpenAlex, Lisa Kamen has authored 12 papers receiving a total of 732 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Psychiatry and Mental health, 4 papers in Cognitive Neuroscience and 2 papers in Pathology and Forensic Medicine. Recurrent topics in Lisa Kamen's work include Migraine and Headache Studies (7 papers), Child Nutrition and Feeding Issues (4 papers) and Autism Spectrum Disorder Research (4 papers). Lisa Kamen is often cited by papers focused on Migraine and Headache Studies (7 papers), Child Nutrition and Feeding Issues (4 papers) and Autism Spectrum Disorder Research (4 papers). Lisa Kamen collaborates with scholars based in United States, Germany and Spain. Lisa Kamen's co-authors include Ronald N. Marcus, Randall Owen, Robert D. McQuade, William H. Carson, George Manos, Michael G. Aman, Elyse Stock, Vladimir Coric, David Kudrow and Peter J. Goadsby and has published in prestigious journals such as The Lancet, Neurology and Journal of the American Academy of Child & Adolescent Psychiatry.

In The Last Decade

Lisa Kamen

9 papers receiving 705 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial

2020 233 citations Robert Croop, Richard B. Lipton et al. The Lancet profile →

Peers

Countries citing papers authored by Lisa Kamen

Since Specialization

Citations

This map shows the geographic impact of Lisa Kamen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lisa Kamen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lisa Kamen more than expected).

Fields of papers citing papers by Lisa Kamen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lisa Kamen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lisa Kamen. The network helps show where Lisa Kamen may publish in the future.

Co-authorship network of co-authors of Lisa Kamen

This figure shows the co-authorship network connecting the top 25 collaborators of Lisa Kamen. A scholar is included among the top collaborators of Lisa Kamen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lisa Kamen. Lisa Kamen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

#	Work	Indexed citations
1	Comparative bioavailability of single‐dose zavegepant during and between migraine attacks: A phase 1, randomized, open‐label, fixed‐sequence, two‐period study 2024 ·Headache The Journal of Head and Face Pain ·Richard Bertz, Julie L. Collins, Jennifer Madonia, Rajinder Bhardwaj, Lisa Kamen, Kyle Matschke, (unknown)	2
2	Long-Term Preventive and Acute Treatment of Migraine With Rimegepant Improves Health Related Quality of Life (P12-12.003) 2023 ·Neurology ·Jelena Pavlović, Ira Turner, Paul Winner, Richard Lipton, Gilbert L’Italien, (unknown), Alexandra Thiry, Lisa Kamen, Robert Croop	0
3	Effects of Rimegepant 75 mg on Monthly Migraine Days: a 52-Week, Open-Label Extension Study (P10-12.010) 2023 ·Neurology ·Robert Croop, Jessica Ailani, David Kudrow, Timothy R. Smith, Richard Lipton, Alexandra Thiry, (unknown), Lisa Kamen	2
4	Rimegepant for the Acute and Preventive Treatment of Migraine in Women: Results From 4 Randomized, Placebo-Controlled Clinical Trials (P9-12.007) 2023 ·Neurology ·Susan Hutchinson, Jelena Pavlović, Jessica Ailani, Kathleen Mullin, Robert Croop, Alexandra Thiry, Beth Morris, Lisa Kamen, (unknown)	1
5	Safety and Tolerability of Rimegepant Every Other Day for Preventive Treatment of Migraine Plus As-Needed for Acute Treatment of Migraine: Results from A 52-Week, Open-Label Extension Phase (P12-12.006) 2023 ·Neurology ·Richard Lipton, David Kudrow, Timothy R. Smith, Jessica Ailani, Peter J. Goadsby, Lisa Kamen, Alexandra Thiry, (unknown), Robert Croop	0
6	A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant for the Preventive Treatment of Migraine (4951) 2021 ·Neurology ·Robert Croop, Richard B. Lipton, Alexandra Thiry, Lisa Kamen, Vlad Coric, Peter J. Goadsby	0
7	Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial breakdown → 2020 ·The Lancet ·Robert Croop, Richard B. Lipton, David Kudrow, David Stock, Lisa Kamen, Charles M. Conway, Elyse Stock, Vladimir Coric, Peter J. Goadsby	233
8	Phase I/II evaluation of intratumoral INT230-6 for the treatment of solid tumors 2018 ·Annals of Oncology ·(unknown), Lillian L. Siu, Nilofer S. Azad, Ian Walters, (unknown), Lisa Kamen, Anthony J. Olszanski	3
9	Aripiprazole in the Treatment of Irritability in Pediatric Patients (Aged 6–17 Years) with Autistic Disorder: Results from a 52-Week, Open-Label Study 2011 ·Journal of Child and Adolescent Psychopharmacology ·Ronald N. Marcus, Randall Owen, George Manos, Raymond Mankoski, Lisa Kamen, Robert D. McQuade, William H. Carson, Patricia K. Corey‐Lisle, Michael G. Aman	57
10	Safety and Tolerability of Aripiprazole for Irritability in Pediatric Patients With Autistic Disorder 2011 ·The Journal of Clinical Psychiatry ·Ronald N. Marcus, Randall Owen, George Manos, Raymond Mankoski, Lisa Kamen, Robert D. McQuade, William H. Carson, Robert L. Findling	63
11	Safety and tolerability of aripiprazole in the treatment of irritability associated with autistic disorder in pediatric patients: Results from a 52-week open-label study 2011 ·European Psychiatry ·(unknown), (unknown), (unknown), George Manos, Robert D. McQuade, Lisa Kamen, Ronald N. Marcus, Raymond Mankoski	1
12	A Placebo-Controlled, Fixed-Dose Study of Aripiprazole in Children and Adolescents With Irritability Associated With Autistic Disorder 2009 ·Journal of the American Academy of Child & Adolescent Psychiatry ·Ronald N. Marcus, Randall Owen, Lisa Kamen, George Manos, Robert D. McQuade, William H. Carson, Michael G. Aman	370

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact